Lexaria Bioscience highlights the rapid growth of the oral GLP-1 pill market, led by Wegovy®, which saw over 600,000 prescriptions in its first two months post-FDA approval in late 2025. The oral GLP-1 sector is expanding faster than injectable forms, with forecasts projecting the market could reach $17 billion to $60 billion by the mid-2030s. Lexaria’s DehydraTECH™ technology aims to enhance the delivery of these oral drugs, positioning the company to benefit from this booming market. Ongoing research and partnerships with pharmaceutical companies are expected to further develop this promising drug delivery platform.
The European Commission has approved Novo Nordisk's Wegovy pill, the first oral GLP-1 receptor agonist for weight management across the EU. This approval covers adults with obesity or overweight with related health issues and follows positive clinica...
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Vivani Medical is developing a semaglutide implant aimed at improving long-term adherence to GLP-1 treatments like Wegovy and Ozempic, which help with obesity and diabetes. The implant, designed to be replaced biannually or annually, could reduce sid...
